Quest Diagnostics/$DGX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Quest Diagnostics

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Ticker

$DGX
Sector

Primary listing

NYSE

Employees

50,500

DGX Metrics

BasicAdvanced
$20B
21.58
$8.35
0.49
$3.10
1.78%

What the Analysts think about DGX

Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.

Bulls say / Bears say

Quest Diagnostics raised its full-year 2025 revenue guidance to $10.80 billion–$10.92 billion and adjusted EPS guidance to $9.63–$9.83 after a 15.2% Q2 revenue increase and 11.5% adjusted EPS growth, underscoring strong demand and execution (Reuters).
The March 2025 collaboration with Google Cloud to deploy generative AI across operations and customer service is expected to enhance data analytics, streamline workflows, and personalize patient experiences, driving productivity gains (FierceBiotech).
The acquisition of Fresenius Medical Care’s kidney dialysis testing portfolio will expand Quest’s end-stage kidney disease testing services and leverage its nationwide lab network to shorten result turnaround times (FierceBiotech).
Executives warned that ongoing tariffs introduced in Q2 are expected to persist through later quarters, potentially increasing operating costs and squeezing margins at Quest Diagnostics (Benzinga).
The Protecting Access to Medicare Act (PAMA) slated for January 2026 could cut Medicare payments by up to 15% on 800 laboratory services, projecting a $100 million impact on Quest’s earnings unless legislative reforms are passed (Investor’s Business Daily).
Organic requisition volume declined 0.9% year-over-year in Q1 2025 despite overall revenue growth, indicating underlying demand softness in core clinical testing services (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

DGX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DGX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DGX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Oct3
Quest Diagnostics
DividendEx-dividend
Oct20
Quest Diagnostics
DividendPayment
$0.80Per share
FAQs